Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN) is a clinical-stage biotechnology company focused on developing innovative therapies for rare and severe neurological disorders. The company leverages its proprietary gene therapy platform to address unmet medical needs, primarily targeting pediatric patients with neurodegenerative and neurogenetic conditions.
Company News
Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 310% increase from Q2 2024. The company expects full-year 2025 revenue of $140-$150 million and continues advancing its clinical pipeline, including the FIREFLY-2 trial for pediatric low-grade glioma treatment.
Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.
Day One Biopharmaceutical (NASDAQ:DAWN) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 1 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Day One Biopharmaceutical. The company has an average price target of $35.25 with a high of $38.00 and a low of $34.00. Below is a summary ...Full story available on Benzinga.com
The clinical-stage biotech released early trial news regarding its lead therapy candidate.